3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
2
CNS
2
Genitourinary
1
Conditions
Carcinoma, Renal Cell
24
Kidney Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
von Hippel-Lindau Disease
2
Neoplasm Metastasis
2
Recurrence
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Neuroectodermal Tumors, Primitive
1
Metastatic Castration-Resistant Prostate Cancer
1
Hemangioblastoma
1
Glioblastoma
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Interventions
spartalizumab
1
pembrolizumab
1
guadecitabine
1
gallium Ga 68 dotatate
1
belzutifan
1
Specimen Handling
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Genetic Testing
1
Fluorodeoxyglucose F18
1
Everolimus
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paraganglioma
×
belzutifan
×
Genitourinary
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled